Cancer Support Services: Hotline and Web Site
The AstraZeneca Cancer Support Network (AZ CSN) provides comprehensive, up-to-date medical and reimbursement information for AstraZeneca oncology products. The AZ CSN is available is available to patients and health care professionals.
Source: Mediwire
By: AstraZeneca Pharmaceuticals LP
The AstraZeneca Cancer Support Network (AZ CSN) provides comprehensive, up-to-date medical and reimbursement information for AstraZeneca oncology products. The AZ CSN is available to patients and health care professionals.
The AstraZeneca Cancer Support Network can help your patients by...
- Verifying prescription drug coverage
- Working directly with your office staff on claims
- Assisting with filling out forms
- Helping patients learn more about their cancer
- Providing information about AstraZeneca clinical trials
- Answering questions about medicines made by AstraZeneca
- Advising patients about helpful support services
- Providing expert advice in more than 150 languages (se habla español)
- Finding out if patients qualify for programs that could help them get the medicines needed if they don't have prescription drug coverage and can't afford their AstraZeneca medication.
The AstraZeneca Cancer Support Network (AZCSN) is provided to health care professionals and patients for informational purposes only. The laws, regulations, and policies pertaining to coverage and reimbursement are subject to change and do change from time to time. Information provided by the AZCSN does not constitute medical or legal advice and is not intended to be a substitute for a consultation with a licensed health care provider, your legal counsel, or applicable third-party payer(s). AstraZeneca reserves the right to modify the AZCSN at any time without notice. For information, please contact the AstraZeneca Cancer Support Network at 1-866-99-AZCSN (1-866-992-9276), Monday through Friday 8:00 AM - 8:00 PM ET. Or, click on the link below to visit the AZCSN Web site. www.AZCSN.net
ICER Finds Insurers Struggled to Provide Fair Access for Obesity Drugs
December 19th 2024The Institute for Clinical and Economic Review assessed the formularies of 11 payers, covering 57 million people, to determine access for drugs that the organization had reviewed in 2022 for cost-effectiveness.
Read More
